Alembic has received approval to demerge the identified real estate undertaking of the company into Shreno, an unlisted public limited company, to be implemented by way of a Scheme of Arrangement. The identified real estate undertaking proposed to be demerged would comprise of the Project Management Consultancy (PMC) business, services of which are provided by the company to Shreno. The Board of Directors of the company at its meeting held on September 11, 2018, approved the same.
Alembic is engaged in manufacturing of active pharmaceutical ingredients for anti-parkinsons, anti-depressants, cephalosporins, macrolides and others.
